InflaRx N.V. (IFRX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.09 (+1.46%), Market cap $0.39B, 52-week low–high $0.73 ~ $2.65.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has complet
Financial statements, price targets, institutional (13F) holdings and related news for InflaRx N.V. are updated in real time on BlackAll Trade.
InflaRx N.V. trades at $2.09 (+1.46%). Real-time quotes and charts are available on BlackAll Trade.
InflaRx N.V. has a market cap of about $0.39B.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to trea